<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">Currently, there is no standard of care for adjuvant/neoadjuvant treatment and although a number of approaches have been attempted including trans-arterial chemoembolization (TACE), Yttrium-90 radioembolization, and neoadjuvant sorafenib in HCC patients on waiting list for liver transplantation [
 <xref ref-type="bibr" rid="CR13">13</xref>â€“
 <xref ref-type="bibr" rid="CR15">15</xref>]. Failure to control micro-metastatic disease is a major determinant influencing early relapse and mortality following curative resection and randomized controlled trials have shown sorafenib, to be ineffective in improving outcomes in the adjuvant setting [
 <xref ref-type="bibr" rid="CR16">16</xref>].
</p>
